Xarelto Lawsuit Numbers Continue To Increase As New Controversies Emerge Surrounding Drug

March 29, 2016 – – BloodThinnerHelp.com reports on an article recently published on Health News Review by a guest blogger psychiatrist from the Washington, DC area. The article discusses what many different media outlets have been reporting recently: controversies surrounding critical clinical trials conducted on blood-thinning drug Xarelto, as well as data which may have been left out of a report to the New England Journal of Medicine.

The subject of these controversies is anticoagulant drug Xarelto, a new-generation blood thinner which was approved by the U.S. Food and Drug administration and released to market in 2011. This approval, however, as is now being discussed, may have been premature due to potentially incomplete clinical trial reports and a potentially faulty testing device during those clinical trials. The trials were meant to compare Xarelto to warfarin, a traditional blood thinner. When the BMJ reported that a malfunctioning blood test device was used during the trial, and that patients in the coumadin group may have been given higher doses of coumadin than what was considered optimal, patients from across the nation began to increasingly question Xarelto.

According to the Health News Review article author, “This isn’t the first time the NEJM has been embroiled in controversy over missing data. The Times referenced a past situation where NEJM editors knew of missing heart attack data from a clinical trial and allowed the study to be published anyway. The drug that was studied, the painkiller Vioxx (rofecoxib), was eventually withdrawn from the market, but not before leading to an estimated 55,000 deaths, as well as thousands of heart attacks and strokes.”

The author continues to discuss new medical reporting ethics which have been brought into question surrounding the drug. The author discusses transparency within data sharing and the importance of this honesty, stating, “As I pointed out in January, the NEJM editors have recently made a case against transparency and data sharing, in opposition to the push for universal acceptance of these principles by many in the research community. After publicly raising concerns that data-sharing would benefit so-called ‘research parasites’ who might have the temerity to use the data ‘to try to disprove what the original investigators had posited,’ Dr. Drazen quickly clarified that his stance against data-sharing didn’t apply to clinical trials such as the Xarelto study.”

These controversies only add to many allegations already surrounding the new-generation blood-thinning drug among patients from across the nation who have stepped forward to file lawsuits alleging that the drug can cause dangerous and even fatal bleeding side effects. Lawsuits now number over 3,400 across the United States, and have been consolidated to form two major groups. Federally-filed cases have been consolidated by the U.S. Judicial Panel on Multidistrict Litigation to form MDL No. 2592 in Eastern Louisiana. They currently number over 2,800 complaints. In addition, more than 600 complaints have been consolidated by the Court of Common Pleas in Philadelphia, Pennsylvania to form a mass tort program.

As many plaintiffs await results of investigations surrounding these new controversies, and await trial dates as well, Attorney Joseph Osborne is working to ensure that anyone else who may have taken Xarelto and suffered from adverse health events that they attribute to their use of the drug will be afforded the important opportunity to fully explore their legal rights at this time. Affected patients may be eligible for significant compensation gained through legal action. To help those wishing to explore this avenue, Attorney Osborne is currently offering free legal consultations for affected parties.

To request additional information concerning Xarelto lawsuits, or to ask questions, please contact Attorney Osborne by calling (866) 425-8902.

###

Contact BloodThinnerHelp.com:

Joseph Osborne
866-425-8902
Mizner Park
433 Plaza Real Blvd., Ste. 271
Boca Raton, FL 33432

ReleaseID: 60008950